

Consolidated Financial Statements for the Year Ended March 31, 2023
FY2023 (April 1, 2022 - March 31, 2023) [UNAUDITED]

May 11, 2023

Company name: Takara Holdings Inc.
 Stock exchange listings: Tokyo Stock Exchange (PRIME section)
 Code number: 2531
 URL: <https://www.takara.co.jp/>
 Company representative: Mutsumi Kimura, President
 Contact: Masakazu Usami, Public Relations& Investor Relations Dept.
 TEL: (075)241-5124
 Annual statement filing date (as planned): Jun 29, 2023

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the year ended March 31, 2023 (April 1, 2022 - March 31, 2023)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ended March 31, 2023		Year ended March 31, 2022	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	350,665	16.5	300,918	8.1
Operating income (loss)	37,945	(12.5)	43,354	100.8
Ordinary income (loss)	38,706	(10.5)	43,230	97.1
Net income (loss) attributable to owners of the parent	21,206	2.1	20,769	96.4
Net income (loss) per share (Yen)	107.26		105.05	
Fully diluted net income per share (Yen)	-		-	
Return on equity		11.0		12.3
Ordinary income to total assets ratio		10.2		12.9
Operating income to net sales ratio		10.8		14.4
Note: Comprehensive income (loss)	41,278	3.2	39,992	145.0
(Reference) Income (loss) from equity method investment	(49)		46	

(2) Consolidated financial position

	As of March 31, 2023	As of March 31, 2022
	(Millions of yen)	(Millions of yen)
Total assets	399,174	362,438
Net assets	255,318	224,555
Equity ratio (%)	51.1	49.8
Net assets per share (Yen)	1,031.60	912.58
(Reference) Equity	203,951	180,420

(3) Consolidated Cash flow

	Year ended March 31, 2023	Year ended March 31, 2022
	(Millions of yen)	(Millions of yen)
Cash flow from operating activities	45,478	16,376
Cash flow from investing activities	(10,474)	(10,399)
Cash flow from financing activities	(22,215)	4,133
Cash and cash equivalents, end of year	91,785	75,729

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2022	Year ended March 31, 2023	Year ending March 31, 2024 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	37.00	38.00	27.00
Annual	37.00	38.00	27.00
Total dividend (Millions of yen)	7,315	7,512	
Payout ratio (%)	35.2	35.4	35.6
Dividend on equity (%)	4.3	3.9	

Note: Correction of dividend forecast from the most recent dividend forecast: Yes

3. Forecast for the year ending March 31, 2024 (April 1, 2023 - March 31, 2024)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2023		Year ending March 31, 2024	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	170,000	3.5	355,000	1.2
Operating income (loss)	11,100	(43.4)	26,300	(30.7)
Ordinary income (loss)	11,400	(42.9)	26,800	(30.8)
Net income (loss) attributable to owners of the parent	6,700	(38.4)	15,000	(29.3)
Net income per share (Yen)	33.89		75.87	

4. Others

(1) Material changes in subsidiaries during this period

(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

(2) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard: Yes

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(3) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included):

As of March 31, 2023 199,699,743 shares

As of March 31, 2022 199,699,743 shares

2) Number of treasury stocks at year end:

As of March 31, 2023 1,995,612 shares

As of March 31, 2022 1,995,577 shares

3) Average number of outstanding shares:

Year ended March 31, 2023 197,704,141 shares

Year ended March 31, 2022 197,704,189 shares

Contents of the attached document

1. Overview of Financial Results.....	2
(1) Overview of Financial Results for the Fiscal Year under Review.....	2
(2) Overview of Financial Position for the Fiscal Year under Review.....	5
(3) Overview of Cash Flows for the Fiscal Year under Review.....	5
(4) Future Outlook.....	5
2. Basic Concept on Selection of Accounting Standards.....	6
3. Consolidated Financial Statements and Primary Notes.....	7
(1) Consolidated Balance Sheets.....	7
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income.....	9
Consolidated Statements of Income.....	9
Consolidated Statements of Comprehensive Income.....	10
(3) Consolidated Statements of Changes in Net Assets.....	11
(4) Consolidated Statements of Cash Flows.....	13
(5) Notes to Consolidated Financial Statements.....	14
(Notes on Premise of Going Concern).....	14
(Changes in Accounting Policies).....	14
(Segment Information).....	14
(Revenue Recognition).....	17
(Per Share Information).....	18
(Significant Subsequent Events).....	18

○Supplement for the Consolidated Financial Statements

1. Overview of Financial Results

(1) Overview of Financial Results for the Fiscal Year under Review

In the fiscal year under review, ended March 31, 2023, the global economy showed a recovery mainly in the U.S. and Europe, but the outlook remained uncertain due to soaring raw material and energy prices, as well as concerns of a global economic recession caused by monetary tightening to curb inflation in the U.S. and Europe.

Under these economic circumstances, the Group has endeavored at the Takara Group Medium-Term Management Plan for FY2021-2023, which serves as the first step in the Group's action plans cited in its long-term management vision, TaKaRa Group Challenge for the 100th, announced in May 2020. In the fiscal year under review, which was the final year of the plan, the Group has been appropriately allocating and investing management resources in areas that should be strengthened, and has been focusing on rebuilding business structures and global corporate functions that consistently generate various forms of value that enhance profitability, while flexibly addressing environmental changes. In this way, the Group has focused on achieving sustainable growth in Japan and overseas and enhancing corporate value.

As a result, in the fiscal year under review, ended March 31, 2023, net sales increased 16.5% year on year to ¥350,665 million, gross profit increased 5.6% year on year to ¥119,941 million, and SG&A expenses increased 16.8% year on year to ¥81,996 million. Operating income decreased 12.5% year on year to ¥37,945 million, ordinary income decreased 10.5% year on year to ¥38,706 million, and net income attributable to owners of the parent increased 2.1% year on year to ¥21,206 million.

Results by business segment were as follows.

[Takara Shuzo]

Takara Shuzo gave the highest priority to supplying safe and secure products as a food manufacturer and focused on improving the product mix by developing new products with differentiation points that are supported by consumers and by nurturing high-profit products. In response to soaring raw material and energy prices, Takara Shuzo has committed to thorough cost reductions and efficiency improvement, as well as maintaining and improving profit margins by revising product prices.

The segment's sales and other information are as shown below.

In shochu, sales decreased due to a decline in sales of large-volume products of *ko*-type shochu and 35% ABV shochu. In sake, although sales of *Sho Chiku Bai Gokai* increased amid a recovery in the eating and drinking establishment market, sales of such products as *Sho Chiku Bai Ten* for household-use decreased, resulting in a decline in overall sales. In light-alcohol refreshers, sales grew as sales of *Takara Shochu Highball*, which is positioned as a core brand, continued to increase, and the launch of *Takara Dry Zero Ball* also contributed. In seasonings, sales increased due to an increase in sales of *Hon Mirin*, food seasonings and other seasonings. In raw alcohol, etc., sales also increased.

As a result, net sales for Takara Shuzo increased 2.7% year on year to ¥122,921 million. Cost of sales increased 3.0% year on year to ¥93,645 million, and gross profit increased 1.6% year on year to ¥29,276 million. As SG&A expenses decreased 1.2% year on year to ¥24,385, affected mainly by decreases in personnel expenses and transportation costs due to more efficient transfer between workplaces, operating income increased 18.3% year on year to ¥4,890 million.

[Takara Shuzo International Group]

The Takara Shuzo International Group engages in the Overseas Alcoholic Beverages Business, which entails exports from Japan and the manufacture and sale of alcoholic beverages in overseas locations, and the Japanese Food Wholesale Business in overseas markets, through which it sells Japanese food ingredients to Japanese food restaurants, retailers, etc. outside Japan.

The segment's sales and other information are as follows:

Overseas Alcoholic Beverages Business

Sales of Blanton's, the premium single-barrel bourbon, remained brisk, while those of Tomatin Scotch whisky also grew. Sales of sake and other Japanese alcoholic beverages declined in China as they were greatly affected by the COVID-19 crisis, but sales of those increased in the U.S., where the market is large. As a result, net sales of the Overseas Alcoholic Beverages Business rose 29.8% year on year to ¥18,253 million.

Japanese Food Wholesale Business in overseas markets

The Japanese Food Wholesale Business in overseas markets engaged in diversification of sales channels, including retail stores and online sales, and development of product procurement and supply systems that meet customer needs, and there were strong sales in the eating and drinking establishment market in the U.S. and Europe, leading to a net sales increase of 35.2% year on year to ¥121,354 million.

As a result, net sales for the Takara Shuzo International Group after the elimination of intersegment transactions rose 34.5% year on year to ¥137,483 million. Cost of sales increased 35.8% year on year to ¥95,088 million, and gross profit rose 31.9% year on year to ¥42,394 million. SG&A expenses rose 33.4% year on year to ¥31,573 million, primarily due to increases in personnel expenses and transportation costs. Accordingly, the Takara Shuzo International Group saw operating income increase 27.7% year on year to ¥10,821 million.

[Takara Bio Group]

The Takara Bio Group is developing reagents/instruments that support research and development activities using biotechnology and providing them to biotech researchers around the world as such activities become increasingly widespread. Furthermore, we are developing CDMO contract services to support the development and manufacture of regenerative and cellular medicine and gene therapy, which have been actively developed by pharmaceutical companies in recent years. CDMO refers to the business of contracting out the processes of pharmaceuticals from formulation development to manufacturing, and the Takara Bio Group is focusing on the field of gene therapy. In addition, in the gene therapy business, the Takara Bio Group is working to maximize the value of our proprietary platform technology for biologics discovery by manufacturing and selling manufacturing aids for gene therapy drugs, creating new modalities (therapeutic means), and advancing new clinical development projects.

In this segment, although sales in the instruments and CDMO businesses decreased, sales in the reagents business increased due to a significant increase in sales of testing-related reagents for COVID-19, including antigen test reagents. Sales in the gene therapy business also increased.

As a result, net sales for the Takara Bio Group increased 15.4% year on year to ¥78,142 million. Cost of sales grew 80.5% year on year to ¥33,377 million mainly due to a change in sales mix, and gross profit decreased 9.0% year on year to ¥44,765 million. SG&A expenses were up 19.3% year on year to ¥24,224 million primarily due to increases in personnel expenses and R&D expenses. Operating income decreased 28.9% year on year to ¥20,541 million.

[Other]

The Other segment includes the real estate rental business, the transportation business, and the wine import and sale business. Net sales of the Other segment increased 0.8% year on year to ¥30,950 million due to continued strong import and sale of wine. Cost of sales increased 0.5% year on year to ¥26,770 million, and gross profit increased 2.1% year on year to ¥4,179 million. SG&A expenses rose 0.8% year on year to ¥1,885 million due to an increase in transportation costs, and operating income was up 3.2% year on year to ¥2,293 million.

Breakdown of sales results by product category

Segment		Previous Fiscal Year (From April 1, 2021 to March 31, 2022)	Fiscal Year under Review (From April 1, 2022 to March 31, 2023)	YoY Comparison
	Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo				
	Shochu	37,935	36,597	(3.5)
	Sake	12,803	12,145	(5.1)
	Light-alcohol refreshers	37,677	40,069	6.3
	Other alcoholic beverages	5,467	5,328	(2.5)
	<i>Hon Mirin</i>	9,097	9,477	4.2
	Other seasonings	8,560	8,780	2.6
	Raw alcohol, etc.	8,168	10,522	28.8
	Total	119,710	122,921	2.7
Takara Shuzo International Group				
	Overseas Alcoholic Beverages Business	14,063	18,253	29.8
	Japanese Food Wholesales Business in overseas markets	89,728	121,354	35.2
	Other	62	2,847	—
	Elimination of intra-Group transaction on consolidation	(1,668)	(4,972)	—
	Total	102,186	137,483	34.5
Takara Bio Group				
	Reagents	52,479	65,925	25.6
	Instruments	1,518	1,375	(9.4)
	CDMO	11,426	8,200	(28.2)
	Gene therapy	2,275	2,640	16.1
	Total	67,699	78,142	15.4
	Reported segment total	289,596	338,547	16.9
	Other	30,719	30,950	0.8
	Segment total	320,315	369,498	15.4
	Sales not allocated to business segments and intersegment transactions	(19,396)	(18,832)	—
	Total	300,918	350,665	16.5

Notes: 1. Amounts include alcohol tax.

2. Net sales of GMP grade (for manufacturing regenerative medical products) reagents, etc., which had been included in Takara Bio Group's "Reagents" until the fiscal year ended March 31, 2022, will be included in "Gene therapy" from the first quarter. The results for the previous fiscal year presented in this table have been restated to reflect this change.

(2) Overview of Financial Position for the Fiscal Year under Review

(Assets)

At the end of the fiscal year under review, current assets totaled ¥241,513 million, an increase of ¥9,189 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in cash and deposits of ¥16,375 million, and decreases in notes and accounts receivable-trade of ¥1,232 million and merchandise and finished goods of ¥5,360 million.

Noncurrent assets were ¥157,661 million, an increase of ¥27,546 million compared with that at the end of the previous fiscal year. This was primarily due to increases of ¥9,143 million in property, plant and equipment and ¥17,831 million in investments and other assets, mainly due to the application of ASC Topic 842, “Leases.”

As a result, total assets were ¥399,174 million, an increase of ¥36,736 million compared with that at the end of the previous fiscal year.

(Liabilities)

At the end of the fiscal year under review, current liabilities totaled ¥67,454 million, a decrease of ¥11,696 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in current portion of bonds of ¥10,000 million.

Noncurrent liabilities were ¥76,401 million, an increase of ¥17,670 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥15,417 million in other noncurrent liabilities mainly due to the application of ASC Topic 842, “Leases.”

As a result, total liabilities were ¥143,856 million, an increase of ¥5,973 million compared with that at the end of the previous fiscal year.

(Net Assets)

At the end of the fiscal year under review, total net assets were ¥255,318 million, an increase of ¥30,762 million compared with that at the end of the previous fiscal year. This was primarily due to increases in retained earnings of ¥13,891 million, foreign currency translation adjustment of ¥9,355 million, and noncontrolling interests of ¥7,231 million.

As a result, the equity ratio totaled 51.1%, compared with 49.8% at the end of the previous fiscal year.

(3) Overview of Cash Flows for the Fiscal Year under Review

Net cash provided by operating activities increased ¥29,101 million year on year to ¥45,478 million primarily due to income before income taxes of ¥39,692 million, depreciation and amortization of ¥9,118 million, a decrease in notes and accounts receivable-trade of ¥2,634 million, a decrease in inventories of ¥8,969 million, an increase in accrued consumption taxes of ¥2,104 million, and income taxes paid of ¥15,535 million.

Net cash used in investing activities resulted in expenditure of ¥10,474 million, an increase in expenditure of ¥74 million compared with that of the previous fiscal year primarily due to payments into time deposits of ¥23,167 million, proceeds from withdrawal of time deposits of ¥24,008 million, purchase of property, plant and equipment and intangible assets of ¥10,618 million, and purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥1,068 million.

Net cash used in financing activities totaled ¥22,215 million (¥4,133 million provided in the previous fiscal year) primarily due to expenditure for redemption of bonds of ¥10,000 million, cash dividends paid of ¥7,305 million, dividends paid to noncontrolling interests of ¥1,579 million, and payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation of ¥1,551 million.

As a result, cash and cash equivalents at fiscal year-end, including effect of exchange rate change on cash and cash equivalents, stood at ¥91,785 million, up ¥16,056 million from the previous fiscal year-end.

(4) Future Outlook

In the fiscal year ending March 31, 2024, Takara Shuzo International Group expects to increase profits in both the Overseas Alcoholic Beverages Business and Japanese Food Wholesale Business in overseas markets by further cultivating existing sales channels, diversifying sales channels, and expanding new sales areas, against the backdrop of the spread of Japanese food overseas.

On the other hand, Takara Shuzo expects to see a decrease in profit due to higher costs for raw materials, containers, and other items, as well as increased investments for safety and security and brand development expenses, despite the positive effects of price revisions implemented in the fiscal year ended March 31, 2023. The Takara Bio Group also expects a decrease in profit due to lower demand for testing-related reagents for COVID-19 and its plans to increase personnel expenses, R&D expenses, and other expenses.

As a result, regards the outlook for results for the following fiscal year, the year ending March 31, 2024, the Group is forecasting net sales of ¥355,000 million, operating income of ¥26,300 million, ordinary income of ¥26,800 million, and net income attributable to owners of the parent of ¥15,000 million. The details of the consolidated results forecasts and the results forecasts for each segment are described on pages 10/15-13/15 in “Supplement for the Consolidated Financial Statements.”

2. Basic Concept on Selection of Accounting Standards

The Takara Group has a policy to prepare the Consolidated Financial Statements in accordance with the Japanese GAAP for the time being, taking into consideration comparability of the Consolidated Financial Statements across periods and companies.

As regards the application of the International Financial Reporting Standards, the Takara Group will take appropriate actions, taking into account the situations in Japan and other countries.

3. Consolidated Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2022	As of Mar. 31, 2023
Assets		
Current assets		
Cash and deposits	80,445	96,820
Notes and accounts receivable-trade	62,856	61,624
Electronically recorded monetary claims-operating	7,403	8,093
Merchandise and finished goods	63,172	57,812
Work in process	2,012	1,718
Raw materials and supplies	7,458	7,372
Other	9,422	8,765
Allowance for doubtful accounts	(449)	(694)
Total current assets	232,323	241,513
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	69,584	76,265
Accumulated depreciation	(36,902)	(39,487)
Buildings and structures, net	32,682	36,778
Machinery, equipment and vehicles	88,453	90,919
Accumulated depreciation	(73,447)	(75,654)
Machinery, equipment and vehicles, net	15,006	15,265
Land	20,170	20,861
Lease assets	1,512	1,520
Accumulated depreciation	(605)	(731)
Lease assets, net	907	789
Construction in progress	1,782	3,662
Other	24,046	28,496
Accumulated depreciation	(14,848)	(16,962)
Other, net	9,198	11,533
Total property, plant and equipment	79,747	88,890
Intangible assets		
Goodwill	10,070	10,668
Other	5,290	5,262
Total intangible assets	15,360	15,931
Investments and other assets		
Investment securities	29,228	30,573
Net defined benefit asset	907	1,054
Deferred tax assets	2,682	2,170
Other	2,253	19,103
Allowance for doubtful accounts	(64)	(64)
Total investments and other assets	35,006	52,838
Total noncurrent assets	130,114	157,661
Total assets	362,438	399,174

(Millions of Yen)

	As of Mar. 31, 2022	As of Mar. 31, 2023
Liabilities		
Current liabilities		
Notes and accounts payable-trade	20,973	21,775
Short-term loans payable	5,497	4,919
Current portion of bonds	10,000	—
Accrued alcohol tax	7,172	5,815
Accrued expenses	5,579	6,368
Income taxes payable	6,602	2,220
Provision for bonuses	3,161	3,380
Other	20,164	22,975
Total current liabilities	79,151	67,454
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	15,248	15,186
Lease obligations	3,005	4,452
Deferred tax liabilities	3,969	4,855
Net defined benefit liability	8,944	8,925
Other	7,562	22,980
Total noncurrent liabilities	58,730	76,401
Total liabilities	137,882	143,856
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,499	1,994
Retained earnings	149,933	163,825
Treasury stock	(1,682)	(1,682)
Total shareholders' equity	163,976	177,363
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	12,216	12,974
Deferred gains or losses on hedges	412	286
Foreign currency translation adjustment	4,330	13,686
Remeasurements of defined benefit plans	(515)	(359)
Total accumulated other comprehensive income	16,443	26,588
Noncontrolling interests	44,135	51,366
Total net assets	224,555	255,318
Total liabilities and net assets	362,438	399,174

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(Millions of Yen)

	FY2022 (Apr. 1, 2021 – Mar. 31, 2022)	FY2023 (Apr. 1, 2022 – Mar. 31, 2023)
Net sales	300,918	350,665
Cost of sales	187,376	230,723
Gross profit	113,541	119,941
Selling, general and administrative expenses	70,187	81,996
Operating income	43,354	37,945
Nonoperating income		
Interest income	176	265
Dividends income	590	800
Rental income from real estate	157	176
Other	568	436
Total nonoperating income	1,492	1,678
Nonoperating expenses		
Interest expenses	330	324
Foreign exchange losses	807	222
Other	477	370
Total nonoperating expenses	1,615	917
Ordinary income	43,230	38,706
Extraordinary income		
Gain on sale of noncurrent assets	88	264
Gain on sale of investment securities	—	674
Insurance claim income	100	678
Other	4,470	63
Total extraordinary income	4,658	1,681
Extraordinary loss		
Loss on sale and retirement of noncurrent assets	407	499
Loss on voluntary product recall	1,190	—
Other	5,329	195
Total extraordinary losses	6,928	694
Income before income taxes	40,961	39,692
Income taxes-current	11,900	10,144
Income taxes-deferred	(309)	857
Total income taxes	11,590	11,001
Net income	29,370	28,690
Net income attributable to the noncontrolling interest	8,601	7,483
Net income attributable to owners of the parent	20,769	21,206

(Consolidated Statements of Comprehensive Income)

(Millions of Yen)

	FY2022 (Apr. 1, 2021 – Mar. 31, 2022)	FY2023 (Apr. 1, 2022– Mar. 31, 2023)
Net income	29,370	28,690
Other comprehensive income		
Valuation difference on available-for-sale securities	845	757
Deferred gains or losses on hedges	219	(125)
Foreign currency translation adjustment	9,189	11,855
Remeasurements of defined benefit plans	367	100
Total other comprehensive income	10,622	12,588
Comprehensive income	39,992	41,278
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	29,349	31,351
Comprehensive income attributable to noncontrolling interest	10,643	9,927

(3) Consolidated Statements of Change in Net Assets

FY2022 (Apr. 1, 2021 – Mar. 31, 2022)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	2,292	135,184	(1,682)	149,020
Cumulative effects of changes in accounting policies			(1,867)		(1,867)
Restated balance	13,226	2,292	133,316	(1,682)	147,152
Changes of items during the period					
Dividends from surplus			(4,151)		(4,151)
Net income			20,769		20,769
Purchase of treasury stock				(0)	(0)
Disposal of treasury stock		0		0	0
Purchase of shares of consolidated subsidiaries		206			206
Net changes of items other than shareholders' equity					
Total changes of items during the period	—	206	16,617	(0)	16,823
Balance at the end of current period	13,226	2,499	149,933	(1,682)	163,976

	Accumulated other comprehensive income					Noncontrolling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	11,370	193	(2,840)	(859)	7,863	34,650	191,535
Cumulative effects of changes in accounting policies							(1,867)
Restated balance	11,370	193	(2,840)	(859)	7,863	34,650	189,667
Changes of items during the period							
Dividends from surplus							(4,151)
Net income							20,769
Purchase of treasury stock							(0)
Disposal of treasury stock							0
Purchase of shares of consolidated subsidiaries							206
Net changes of items other than shareholders' equity	845	219	7,171	343	8,580	9,484	18,064
Total changes of items during the period	845	219	7,171	343	8,580	9,484	34,888
Balance at the end of current period	12,216	412	4,330	(515)	16,443	44,135	224,555

FY2023 (Apr. 1, 2022 – Mar. 31, 2023)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	2,499	149,933	(1,682)	163,976
Changes of items during the period					
Dividends from surplus			(7,315)		(7,315)
Net income			21,206		21,206
Purchase of treasury stock				(0)	(0)
Disposal of treasury stock		0		0	0
Purchase of shares of consolidated subsidiaries		(505)			(505)
Net changes of items other than shareholders' equity					
Total changes of items during the period	—	(505)	13,891	(0)	13,386
Balance at the end of current period	13,226	1,994	163,825	(1,682)	177,363

	Accumulated other comprehensive income					Noncontrolling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	12,216	412	4,330	(515)	16,443	44,135	224,555
Changes of items during the period							
Dividends from surplus							(7,315)
Net income							21,206
Purchase of treasury stock							(0)
Disposal of treasury stock							0
Purchase of shares of consolidated subsidiaries							(505)
Net changes of items other than shareholders' equity	757	(125)	9,355	156	10,144	7,231	17,375
Total changes of items during the period	757	(125)	9,355	156	10,144	7,231	30,762
Balance at the end of current period	12,974	286	13,686	(359)	26,588	51,366	255,318

(4) Consolidated Statements of Cash Flows

(Millions of Yen)

	FY2022 (Apr. 1, 2021– Mar. 31, 2022)	FY2023 (Apr. 1, 2022– Mar. 31, 2023)
Net cash provided by (used in) operating activities		
Income before income taxes	40,961	39,692
Depreciation and amortization	8,425	9,118
Impairment loss	185	—
Amortization of goodwill	875	998
Increase (decrease) in provision for sales promotion expenses	(2,049)	—
Interest and dividends income	(767)	(1,066)
Interest expenses	330	324
Insurance claim income	(100)	(678)
Loss (gain) on sale and retirement of non-current assets	319	235
Loss (gain) on sale of investment securities	—	(674)
Decrease (increase) in notes and accounts receivable-trade	(7,109)	2,634
Decrease (increase) in inventories	(21,235)	8,969
Increase (decrease) in notes and accounts payable-trade	3,920	(252)
Increase (decrease) in liquor taxes payable	281	(1,358)
Increase (decrease) in accrued consumption taxes	(1,890)	2,104
Increase (decrease) in other current liabilities	3,372	(1,261)
Other, net	(112)	835
Subtotal	25,406	59,621
Interest and dividends income received	787	1,053
Interest expenses paid	(334)	(340)
Income taxes paid	(10,253)	(15,535)
Proceeds from insurance income	100	678
Subsidies received	671	—
Net cash provided by (used in) operating activities	16,376	45,478
Net cash provided by (used in) investing activities		
Payments into time deposits	(15,513)	(23,167)
Proceeds from withdrawal of time deposits	14,758	24,008
Purchase of property, plant and equipment and intangible assets	(14,762)	(10,618)
Proceeds from sale of property, plant and equipment and intangible assets	1,326	430
Purchase of investment securities	(43)	(517)
Proceeds from sale of investment securities	—	793
Purchase of shares of subsidiaries resulting in change in scope of consolidation	—	(1,068)
Other, net	3,834	(334)
Net cash provided by (used in) investing activities	(10,399)	(10,474)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term borrowings	66	(435)
Repayments of long-term borrowings	(55)	(363)
Proceeds from issuance of bonds	9,927	—
Redemption of bonds	—	(10,000)
Cash dividends paid	(4,147)	(7,305)
Dividends paid to noncontrolling interests	(763)	(1,579)
Repayments of lease obligations	(710)	(919)
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	(175)	(1,551)
Other, net	(8)	(61)
Net cash provided by (used in) financing activities	4,133	(22,215)
Effect of exchange rate change on cash and cash equivalents	2,758	3,267
Net increase (decrease) in cash and cash equivalents	12,869	16,056
Cash and cash equivalents at beginning of period	62,860	75,729
Cash and cash equivalents at end of period	75,729	91,785

(5) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Changes in Accounting Policies)

(Application of ASC Topic 842, “Leases”)

Overseas subsidiaries that apply U.S. GAAP adopted ASC Topic 842, “Leases” (hereinafter referred to as the “Standard”), from the fiscal year under review. Accompanying this, regarding lease transactions of lessees, all leases are recognized as assets and liabilities in principle.

The method of recognizing the cumulative impact due to the adoption of the Standard on the commencement date of adoption, which is permitted as an interim measure, was employed for the adoption of the Standard.

As a result, in the consolidated balance sheet for the fiscal year under review, “Other” under investments and other assets, “Other” under current liabilities, and “Other” under noncurrent liabilities increased by ¥16,531 million, ¥1,350 million, and ¥15,234 million, respectively. The impact on profit or loss and per share information for the fiscal year under review is immaterial.

(Segment Information)

1. Overview of Reported Segments

Reporting segments are the segments of the Takara Group for which financial information can be obtained. The Board of Directors, the top organization for decision making on Group management, examines such information to determine the allocation of management resources and evaluate the business performance on a regular basis.

The Group consists of the corporate groups centered on the operating companies Takara Shuzo Co., Ltd., Takara Shuzo International Co., Ltd. and Takara Bio Inc.; other businesses; and the Company, which manages the whole group as the holding company. All operating companies develop comprehensive business strategies, covering both domestic and overseas operations, for the goods, products and services that they offer, and work to expand their business operations. Accordingly, the Group has defined three reported segments based on the content of goods, products and services, while taking into consideration the scope of managerial responsibility and the capacity to evaluate business performance. These three reported segments are Takara Shuzo, the Takara Shuzo International Group, and the Takara Bio Group.

Takara Shuzo primarily engages in the manufacture and sale of alcoholic beverages and seasonings in Japan. The Takara Shuzo International Group engages in the export of alcoholic beverages from Japan, the manufacture and sale of alcoholic beverages at overseas locations, and the Japanese Food Wholesale Business in overseas markets. The Takara Bio Group engages in development of basic technologies for bio drug discovery through the business of reagents and instruments as well as CDMO services.

2. Calculation method for net sales, income or loss, assets, and other items of each reported segment

The accounting treatment of reported business segments is generally the same as that explained in “Basis of Presentation of Consolidated Financial Statements.”

The figures for the income of reported segments are based on operating income. Intersegment income is based on the prevailing market price.

3. Net sales, Income (Loss), Assets and Other items by Reported Segment
Previous Fiscal Year (From April 1, 2021, to March 31, 2022)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	118,889	101,920	67,699	288,510	12,408	300,918	—	300,918
Intersegment	820	265	0	1,086	18,310	19,396	(19,396)	—
Total	119,710	102,186	67,699	289,596	30,719	320,315	(19,396)	300,918
Segment income (loss)	4,135	8,472	28,902	41,510	2,222	43,733	(379)	43,354
Segment assets	90,442	89,836	115,712	295,991	19,836	315,827	46,610	362,438
Other items								
Depreciation and amortization	2,590	1,675	3,554	7,820	238	8,059	366	8,425
Amortization of goodwill	—	374	500	875	—	875	—	875
Investment in equity- method affiliates	—	—	—	—	—	—	1,769	1,769
Increase in total fixed assets, property, plant and equipment and intangible assets	1,785	844	13,180	15,810	208	16,018	194	16,213

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2 Details of adjustment amounts are as follows.

- (1) Segment income (loss) comprises intersegment eliminations of ¥34 million and loss of the Company not allocated to business segments of ¥(413) million.
 - (2) Segment assets include assets of the Company not allocated to business segments of ¥75,059 million and other adjustment (principally intersegment eliminations) of ¥(28,449) million. Assets attributed to the Company include surplus funds and long-term investment assets.
 - (3) Depreciation and amortization primarily comprises depreciation and amortization recognized by the Company.
 - (4) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.
 - (5) Increase in total fixed assets, property, plant and equipment and intangible assets is primarily the increase recorded by the Company.
3. Segment income (loss) has been adjusted to the operating income of consolidated financial statements.

Fiscal Year under Review (From April 1, 2022, to March 31, 2023)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	122,116	137,256	78,139	337,512	13,152	350,665	—	350,665
Intersegment	805	226	2	1,035	17,797	18,832	(18,832)	—
Total	122,921	137,483	78,142	338,547	30,950	369,498	(18,832)	350,665
Segment income (loss)	4,890	10,821	20,541	36,252	2,293	38,546	(601)	37,945
Segment assets	89,979	121,348	129,202	340,530	18,849	359,380	39,794	399,174
Other items								
Depreciation and amortization	2,467	2,043	4,050	8,561	230	8,791	326	9,118
Amortization of goodwill	—	399	599	998	—	998	—	998
Investment in equity- method affiliates	—	—	—	—	—	—	1,715	1,715
Increase in total fixed assets, property, plant and equipment and intangible assets	2,763	4,704	6,516	13,985	100	14,085	79	14,165

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2 Details of adjustment amounts are as follows.

- (1) Segment income (loss) comprises intersegment eliminations of ¥57 million and loss of the Company not allocated to business segments of ¥(658) million.
 - (2) Segment assets include assets of the Company not allocated to business segments of ¥64,793 million and other adjustment (principally intersegment eliminations) of ¥(24,999) million. Assets attributed to the Company include surplus funds and long-term investment assets.
 - (3) Depreciation and amortization primarily comprises depreciation and amortization recognized by the Company.
 - (4) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.
 - (5) Increase in total fixed assets, property, plant and equipment and intangible assets is primarily the increase recorded by the Company.
3. Segment income (loss) has been adjusted to the operating income of consolidated financial statements.

(Revenue Recognition)

1. Information on breakdown of revenue from contracts with customers

Previous Fiscal Year (From April 1, 2021, to March 31, 2022)

(Millions of yen)

	Reported Segment				Other (Note)	Total
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal		
Alcoholic Beverages Business	118,889	12,194	—	131,084	4,542	135,626
Japanese Food Wholesales Business in overseas markets	—	89,725	—	89,725	—	89,725
Bio	—	—	67,699	67,699	—	67,699
Other	—	—	—	—	7,261	7,261
Revenue earned from contracts with customers	118,889	101,920	67,699	288,510	11,803	300,313
Other revenue	—	—	—	—	605	605
Net sales to external customers	118,889	101,920	67,699	288,510	12,408	300,918

Note: Other includes business segments that are not part of reported segments, under which revenue from the import and sale of wine and from freight delivery services is included in “Revenue earned from contracts with customers,” and revenue from real estate rental is included in “Other revenue” based on ASBJ Statement No. 13 “Accounting Standard for Lease Transactions.”

Fiscal Year under Review (From April 1, 2022, to March 31, 2023)

(Millions of yen)

	Reported Segment				Other (Note)	Total
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal		
Alcoholic Beverages Business	122,116	15,905	—	138,021	5,298	143,320
Japanese Food Wholesales Business in overseas markets	—	121,351	—	121,351	—	121,351
Bio	—	—	78,139	78,139	—	78,139
Other	—	—	—	—	7,245	7,245
Revenue earned from contracts with customers	122,116	137,256	78,139	337,512	12,543	350,056
Other revenue	—	—	—	—	609	609
Net sales to external customers	122,116	137,256	78,139	337,512	13,152	350,665

Note: Other includes business segments that are not part of reported segments, under which revenue from the import and sale of wine and from freight delivery services is included in “Revenue earned from contracts with customers,” and revenue from real estate rental is included in “Other revenue” based on ASBJ Statement No. 13 “Accounting Standard for Lease Transactions.”

(Per Share Information)

	Previous Fiscal Year (From April 1, 2021, to March 31, 2022)	Fiscal Year under Review (From April 1, 2022, to March 31, 2023)
Net assets per share	¥912.58	¥1,031.60
Profit per share	¥105.05	¥107.26

Notes: 1. Fully diluted profit per share is not presented since there were no potential shares.

2. The basis of calculation of net assets per share is as follows.

	Previous Fiscal Year (As of March 31, 2022)	Fiscal Year under Review (As of March 31, 2023)
Total net assets (¥ million)	224,555	255,318
Amount deducted from total net assets (¥ million)	44,135	51,366
(of which minority interests) (¥ million)	(44,135)	(51,366)
Net assets at term-end related to shares of common stock (¥ million)	180,420	203,951
Shares of common stock at term-end used to calculate net assets per share (1,000 shares)	197,704	197,704

3. The basis of calculation of net income per share and fully diluted net income per share is as follows.

	Previous Fiscal Year (From April 1, 2021, to March 31, 2022)	Fiscal Year under Review (From April 1, 2022, to March 31, 2023)
Net income attributable to owners of the parent (¥ million)	20,769	21,206
Amount not belonging to common shareholders (¥ million)	—	—
Net income related to shares of common stock (¥ million)	20,769	21,206
Average number of shares outstanding during the term (1,000 shares)	197,704	197,704

(Significant Subsequent Events)

No items to report.

2023年3月期 決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Year Ended March 31, 2023

1. 宝ホールディングス(連結)

Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書

Consolidated Statements of Income by Business Group (Summary)

② 要約貸借対照表

Consolidated Balance Sheets (Summary)

2. 宝酒造

Takara Shuzo

要約損益計算書

Statements of Income (Summary)

3. 宝酒造インターナショナルグループ

Takara Shuzo International Group

要約損益計算書

Statements of Income (Summary)

4. タカラバイオグループ

Takara Bio Group

要約損益計算書

Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)

Six-Year Financial Summary by Business Group

6. 2023年3月期 参考資料

Reference Data for the Year Ended March 31, 2023

7. 2024年3月期 業績予想

Financial forecast for the year ending March 31, 2024

① 宝ホールディングス(連結)

Takara Holdings Inc. - Consolidated -

② 宝酒造

Takara Shuzo

③ 宝酒造インターナショナルグループ

Takara Shuzo International Group

④ タカラバイオグループ

Takara Bio Group

8. 2024年3月期 参考資料

Reference Data for the year ending March 31, 2024

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

広報・IR部 Public Relations & Investor Relations Dept.

TEL 075(241)5124
FAX 075(241)5126
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社 広報・IR部

Takara Holdings Inc. Public Relations&Investor Relations Dept.

TEL 075(241)5124 FAX 075(241)5126

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	2022年3月期 FY2022	2023年3月期 FY2023/ Apr. 1, 2022 - Mar. 31, 2023		対前期 Change from FY2022		対2/9予想 Change from forecast announced Feb. 2023	
	実績 Actual (a)	2/9予想 Forecast announced Feb. 9, 2023 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
宝酒造 Takara Shuzo	119,710	122,385	122,921	3,211	2.7%	536	0.4%
宝酒造インターナショナルグループ Takara Shuzo International Group	102,186	137,393	137,483	35,297	34.5%	90	0.1%
タカラバイオ グループ Takara Bio Group	67,699	78,700	78,142	10,442	15.4%	△ 557	△0.7%
その他 Other	30,719	30,711	30,950	230	0.8%	239	0.8%
調整額 Adjustment	△ 19,396	△ 19,189	△ 18,832	564	—	356	—
売上高 Net sales	300,918	350,000	350,665	49,746	16.5%	665	0.2%
売上原価 Cost of sales	187,376	230,300	230,723	43,346	23.1%	423	0.2%
売上総利益 Gross profit	113,541	119,700	119,941	6,399	5.6%	241	0.2%
運送費、保管料 Transportation and storage	12,076	13,100	13,119	1,042	8.6%	19	0.1%
広告宣伝費 Advertising	2,510	2,700	2,840	329	13.1%	140	5.2%
販売促進費 Sales promotion	3,883	4,200	4,220	337	8.7%	20	0.5%
研究開発費 Research and development	6,484	9,000	8,949	2,464	38.0%	△ 50	△0.6%
管理費、その他 Other, net	45,232	53,900	52,866	7,633	16.9%	△ 1,033	△1.9%
販売費及び一般管理費 SG&A expenses	70,187	82,900	81,996	11,808	16.8%	△ 903	△1.1%
宝酒造 Takara Shuzo	4,135	4,363	4,890	754	18.3%	527	12.1%
宝酒造インターナショナルグループ Takara Shuzo International Group	8,472	10,820	10,821	2,348	27.7%	1	0.0%
タカラバイオ グループ Takara Bio Group	28,902	20,000	20,541	△ 8,360	△28.9%	541	2.7%
その他 Other	2,222	2,261	2,293	71	3.2%	32	1.5%
調整額 Adjustment	△ 379	△ 644	△ 601	△ 222	—	42	—
営業利益(△:損失) Operating income(△:loss)	43,354	36,800	37,945	△ 5,408	△12.5%	1,145	3.1%
受取利息・配当金 Interest and Dividends income	767	1,000	1,066	298	38.9%	66	6.6%
その他営業外収益 Other, net	725	500	612	△ 112	△15.6%	112	22.5%
営業外収益 Non-operating income	1,492	1,500	1,678	185	12.5%	178	11.9%
支払利息 Interest and discounts expenses	330	300	324	△ 6	△1.8%	24	8.3%
その他営業外費用 Other, net	1,284	600	593	△ 691	△53.9%	△ 6	△1.2%
営業外費用 Non-operating expenses	1,615	900	917	△ 698	△43.2%	17	2.0%
経常利益(△:損失) Ordinary income(△:loss)	43,230	37,400	38,706	△ 4,524	△10.5%	1,306	3.5%
特別利益 Extraordinary income	4,658	1,100	1,681	△ 2,977	△63.9%	581	52.8%
特別損失 Extraordinary loss	6,928	600	694	△ 6,233	△90.0%	94	15.8%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	40,961	37,900	39,692	△ 1,268	△3.1%	1,792	4.7%
法人税、住民税及び事業税 Current income taxes	11,900	11,700	10,144	△ 1,755	△14.8%	△ 698	△6.0%
法人税等調整額 Deferred income taxes	△ 309		857	1,166	—		
当期純利益(△:損失) Net income(△:loss)	29,370	26,200	28,690	△ 679	△2.3%	2,490	9.5%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	8,601	6,800	7,483	△ 1,117	△13.0%	683	10.1%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	20,769	19,400	21,206	437	2.1%	1,806	9.3%
設備投資額(有形・無形) Capital expenditures	16,213	16,395	14,165	△ 2,047	△12.6%	△ 2,229	△13.6%
減価償却費(有形・無形) Depreciation and Amortization	8,425	9,100	9,118	693	8.2%	18	0.2%
のれん償却額 Amortization of goodwill	875	1,000	998	123	14.1%	△ 1	△0.1%
営業外収益 Non-operating income	受取利息 265、受取配当金 800 など Interest income 265, Dividends income 800, etc.						
営業外費用 Non-operating expenses	支払利息 275、社債利息 49、為替差損 222 など Interest expense 275, Interest on bonds 49, Foreign exchange losses 222 etc.						
特別利益 Extraordinary income	受取保険金 678、投資有価証券売却益 674 など (前期:国庫補助金 4,470 など) Insurance claim income 678, Gain on sale of investment securities 674 etc. (FY2022:National subsidies 4,470 etc.)						
特別損失 Extraordinary loss	固定資産売却損 499 など (前期:固定資産圧縮損 4,470、製品自主回収関連 1,190 など) Loss on sales and retirement of non-current assets 499, etc. (FY2022:Loss on tax purpose reduction entry of non-current assets 4,470, Loss on product recall 1,190, etc.)						

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets

(百万円 :Millions of Yen)

	2022年3月期 3月期末 As of Mar. 31, 2022	2023年3月期 3月期末 As of Mar. 31, 2023	増減 Change	主な増減理由 Reference
(流動資産) (Total current assets)	232,323	241,513	9,189	(億円 :One hundred millions of Yen)
現金及び預金 Cash and deposits	80,445	96,820	16,375	TH △96.6、TB +282.1
受取手形及び売掛金 Notes and accounts receivable-trade	70,260	69,717	△ 542	TS △6.3、TSI +54.3、TB △52.7
有価証券 Marketable securities	1,179	459	△ 719	
棚卸資産 Inventories	72,643	66,904	△ 5,739	TB △129.7
その他 Other current assets	8,243	8,305	61	
貸倒引当金 Allowance for doubtful accounts	△ 449	△ 694	△ 244	
(固定資産) (Total fixed assets)	130,114	157,661	27,546	
〔有形固定資産〕 [Property, plant and equipment]	79,747	88,890	9,143	(当期の有形・無形固定資産の主な増減内訳) Reference of Property, plant and equipment and Intangible assets 新規取得 TS+27.6、TSI+47.0、TB+65.1 Newly purchases 減価償却 TS△24.6、TSI△20.4、TB△40.5 Depreciation
建物及び構築物 Buildings and structures	32,682	36,778	4,095	
機械装置及び運搬具 Machinery, equipment and vehicle	15,006	15,265	259	
土地 Land	20,170	20,861	691	
その他 Other property, plant and equipment	11,888	15,985	4,097	
〔無形固定資産〕 [Intangible fixed assets]	15,360	15,931	571	
のれん Goodwill	10,070	10,668	598	
その他 Other intangible fixed assets	5,290	5,262	△ 27	
〔投資その他の資産〕 [Investments and other assets]	35,006	52,838	17,831	
投資有価証券 Investment securities	29,228	30,573	1,345	うち 時価評価 TH +8.7 TS +1.5 Market valuation
その他 Other assets	5,843	22,328	16,485	
貸倒引当金 Allowance for doubtful accounts	△ 64	△ 64	—	
資産合計 Total assets	362,438	399,174	36,736	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産の部 :Liabilities and net assets

(百万円 :Millions of Yen)

	2022年3月期 3月期末 As of Mar. 31, 2022	2023年3月期 3月期末 As of Mar. 31, 2023	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	79,151	67,454	△ 11,696	(億円 :One hundred millions of Yen)
支払手形及び買掛金 Notes and accounts payable-trade	20,973	21,775	802	
短期借入金 Short-term loans payable	5,497	4,919	△ 578	
1年内償還予定の社債 Current portion of bonds	10,000	—	△ 10,000	TH △100.0(第13,14回普通社債 2022年4月償還) (#13,14SB Redemption Apr.2022)
未払酒税 Accrued alcohol tax	7,172	5,815	△ 1,357	
未払費用 Accrued expenses	5,579	6,368	788	
その他 Other current liabilities	29,928	28,576	△ 1,352	
(固定負債) (Total non-current liabilities)	58,730	76,401	17,670	
社債 Bonds payable	20,000	20,000	—	
長期借入金 Long-term loans payable	15,248	15,186	△ 61	
退職給付に係る負債 Net defined benefit liability	8,944	8,925	△ 19	
預り金 Deposits from customers	5,089	5,087	△ 2	
その他 Other non-current liabilities	9,447	27,201	17,753	
負債合計 Total liabilities	137,882	143,856	5,973	
資本金 Capital stock	13,226	13,226	—	
資本剰余金 Capital surplus	2,499	1,994	△ 505	
利益剰余金 Retained earnings	149,933	163,825	13,891	
自己株式 Treasury stock	△ 1,682	△ 1,682	△ 0	
(株主資本) (Total owner's equity)	163,976	177,363	13,386	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	12,216	12,974	757	
繰延ヘッジ損益 Deferred gains or losses on hedges	412	286	△ 125	
為替換算調整勘定 Translation adjustments	4,330	13,686	9,355	TSI +66.3、TB +27.2 USD=132.70JPY, EUR=141.44JPY, GBP=160.01JPY (2022年12月) USD=115.02JPY, EUR=130.52JPY, GBP=155.24JPY (2021年12月)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 515	△ 359	156	
(その他の包括利益累計額) (Total valuation and translation adjustments)	16,443	26,588	10,144	
(非支配株主持分) (Noncontrolling interests)	44,135	51,366	7,231	
純資産合計 Total net assets	224,555	255,318	30,762	
負債純資産合計 Total liabilities and net assets	362,438	399,174	36,736	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2022年3月期 FY2022	2023年3月期 FY2023/ Apr. 1, 2022 - Mar. 31, 2023		対前期 Change from FY2022		対2/9予想 Change from forecast announced Feb. 2023	
	実績 Actual (a)	2/9予想 Forecast announced Feb. 9, 2023 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
焼酎 Shochu	37,935	36,481	36,597	△ 1,337	△ 3.5%	116	0.3%
清酒 Sake	12,803	12,070	12,145	△ 658	△ 5.1%	75	0.6%
ソフトアルコール飲料 Light-alcohol refreshers	37,677	40,061	40,069	2,392	6.3%	8	0.0%
その他酒類 Other liquors	5,467	5,255	5,328	△ 138	△ 2.5%	73	1.4%
本みりん Hon Mirin	9,097	9,329	9,477	380	4.2%	148	1.6%
その他調味料 Other seasonings	8,560	8,741	8,780	220	2.6%	39	0.5%
原料用アルコール等 Raw alcohol	8,168	10,445	10,522	2,353	28.8%	77	0.7%
売上高 Net sales	119,710	122,385	122,921	3,211	2.7%	536	0.4%
売上原価 Cost of sales	90,898	93,611	93,645	2,747	3.0%	34	0.0%
売上総利益 Gross profit	28,811	28,774	29,276	464	1.6%	502	1.7%
運送費、保管料 Transportation and storage	8,134	7,898	7,857	△ 276	△ 3.4%	△ 40	△ 0.5%
広告宣伝費 Advertising	2,327	2,533	2,626	298	12.8%	93	3.7%
販売促進費 Sales promotion	2,423	2,489	2,457	34	1.4%	△ 31	△ 1.3%
研究開発費 Research and development	366	370	367	1	0.3%	△ 2	△ 0.7%
管理費、その他 Other, net	11,425	11,121	11,076	△ 348	△ 3.1%	△ 44	△ 0.4%
販売費及び一般管理費 SG&A expenses	24,676	24,411	24,385	△ 290	△ 1.2%	△ 25	△ 0.1%
営業利益(△:損失) Operating income(△:loss)	4,135	4,363	4,890	754	18.3%	527	12.1%
営業外収益 Non-operating income	281	473	544	263	93.3%	71	15.2%
営業外費用 Non-operating expenses	346	502	567	220	63.6%	65	13.1%
経常利益(△:損失) Ordinary income(△:loss)	4,070	4,334	4,867	797	19.6%	533	12.3%
特別利益 Extraordinary gain	110	63	63	△ 47	△ 43.1%	0	0.2%
特別損失 Extraordinary loss	1,321	255	234	△ 1,087	△ 82.2%	△ 20	△ 7.9%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	2,859	4,142	4,696	1,836	64.2%	554	13.4%
法人税、住民税及び事業税 Current income taxes	1,007	1,430	1,277	269	26.8%	28	2.0%
法人税等調整額 Deferred income taxes	△ 96		181	277	—		
当期純利益(△:損失) Net income(△:loss)	1,948	2,712	3,237	1,289	66.2%	525	19.4%
設備投資額(有形・無形) Capital expenditures	1,785	4,008	2,763	978	54.8%	△ 1,244	△ 31.0%
減価償却費(有形・無形) Depreciation and Amortization	2,590	2,485	2,467	△ 122	△ 4.7%	△ 17	△ 0.7%

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2022年3月期 FY2022	2023年3月期 FY2023/ Apr. 1, 2022 - Mar. 31, 2023		対前期 Change from FY2022		対2/9予想 Change from forecast announced Feb. 2023	
	実績 Actual (a)	2/9予想 Forecast announced Feb. 9, 2023 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
海外酒類事業 Overseas Alcoholic beverages business	14,063	18,219	18,253	4,189	29.8%	34	0.2%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	89,728	121,440	121,354	31,626	35.2%	△ 85	△ 0.1%
その他 Other	62	2,845	2,847	2,785	4,475.1%	2	0.1%
連結消去 Elimination	△ 1,668	△ 5,111	△ 4,972	△ 3,303	—	138	—
売上高 Net sales	102,186	137,393	137,483	35,297	34.5%	90	0.1%
売上原価 Cost of sales	70,045	95,012	95,088	25,043	35.8%	76	0.1%
売上総利益 Gross profit	32,140	42,381	42,394	10,254	31.9%	13	0.0%
運送費、保管料 Transportation and storage	3,490	4,908	4,883	1,393	39.9%	△ 24	△ 0.5%
広告宣伝費 Advertising	112	137	136	24	21.4%	△ 0	△ 0.5%
販売促進費 Sales promotion	812	1,024	1,109	297	36.6%	85	8.4%
管理費、その他 Other, net	19,253	25,492	25,443	6,190	32.2%	△ 48	△ 0.2%
販売費及び一般管理費 SG&A expenses	23,667	31,561	31,573	7,905	33.4%	12	0.0%
海外酒類事業 Overseas Alcoholic beverages business	3,781	4,902	4,895	1,114	29.5%	△ 6	△ 0.1%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	6,112	7,621	7,559	1,446	23.7%	△ 61	△ 0.8%
その他 Other	△ 933	1,635	1,700	2,634	—	65	4.0%
連結消去 Elimination	△ 487	△ 3,339	△ 3,334	△ 2,846	—	4	—
営業利益(△:損失) Operating income(△:loss)	8,472	10,820	10,821	2,348	27.7%	1	0.0%
営業外収益 Non-operating income	297	261	315	18	6.1%	54	21.0%
営業外費用 Non-operating expenses	309	189	169	△ 139	△ 45.2%	△ 19	△ 10.3%
経常利益(△:損失) Ordinary income(△:loss)	8,461	10,892	10,967	2,506	29.6%	75	0.7%
特別利益 Extraordinary gain	3	15	8	5	183.1%	△ 6	△ 43.3%
特別損失 Extraordinary loss	202	67	68	△ 134	△ 66.2%	1	2.1%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	8,261	10,840	10,907	2,645	32.0%	67	0.6%
法人税、住民税及び事業税 Current income taxes	2,159	3,163	3,255	1,096	50.8%	121	3.8%
法人税等調整額 Deferred income taxes	△ 49		28	78	—		
当期純利益(△:損失) Net income(△:loss)	6,151	7,677	7,623	1,471	23.9%	△ 53	△ 0.7%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	783	1,142	1,189	405	51.7%	47	4.1%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	5,368	6,535	6,434	1,066	19.9%	△ 100	△ 1.5%
設備投資額(有形・無形) Capital expenditures	844	2,111	4,704	3,860	457.4%	2,593	122.8%
減価償却費(有形・無形) Depreciation and Amortization	1,675	2,017	2,043	367	22.0%	26	1.3%
のれん償却額 Amortization of goodwill	374	403	399	24	6.5%	△ 3	△ 0.9%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2022年3月期 FY2022	2023年3月期 FY2023/ Apr. 1, 2022 - Mar. 31, 2023		対前期 Change from FY2022		対2/9予想 Change from forecast announced Feb. 2023	
	実績 Actual (a)	2/9予想 Forecast announced Feb. 9, 2023 (b)	実績 Actual (c)	増減 Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減 Difference (c-b)	率(c/b-1) YOY% (c/b-1)
試薬 Reagents	52,479	66,275	65,925	13,446	25.6%	△ 349	△ 0.5%
機器 Instruments	1,518	1,550	1,375	△ 142	△ 9.4%	△ 174	△ 11.3%
受託 CDMO	11,426	8,242	8,200	△ 3,226	△ 28.2%	△ 42	△ 0.5%
遺伝子医療 Gene Therapy	2,275	2,631	2,640	365	16.1%	8	0.3%
売上高 Net sales	67,699	78,700	78,142	10,442	15.4%	△ 557	△ 0.7%
売上原価 Cost of sales	18,488	33,642	33,377	14,888	80.5%	△ 265	△ 0.8%
売上総利益 Gross profit	49,211	45,057	44,765	△ 4,445	△ 9.0%	△ 291	△ 0.6%
運送費、保管料 Transportation and storage	755	680	653	△ 102	△ 13.6%	△ 27	△ 4.1%
広告宣伝費 Advertising	58	48	48	△ 9	△ 16.5%	△ 0	△ 0.6%
販売促進費 Sales promotion	683	747	699	15	2.3%	△ 47	△ 6.4%
研究開発費 Research and development	6,109	8,654	8,575	2,466	40.4%	△ 78	△ 0.9%
管理費、その他 Other, net	12,702	14,925	14,247	1,544	12.2%	△ 678	△ 4.5%
販売費及び一般管理費 SG&A expenses	20,309	25,057	24,224	3,914	19.3%	△ 832	△ 3.3%
営業利益(△:損失) Operating income(△:loss)	28,902	20,000	20,541	△ 8,360	△ 28.9%	541	2.7%
営業外収益 Non-operating income	357	320	363	5	1.5%	43	13.5%
営業外費用 Non-operating expenses	800	220	221	△ 578	△ 72.3%	1	0.8%
経常利益(△:損失) Ordinary income(△:loss)	28,459	20,100	20,682	△ 7,777	△ 27.3%	582	2.9%
特別利益 Extraordinary income	4,476	914	930	△ 3,545	△ 79.2%	16	1.8%
特別損失 Extraordinary loss	5,403	274	388	△ 5,014	△ 92.8%	114	41.7%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	27,532	20,739	21,224	△ 6,308	△ 22.9%	484	2.3%
法人税、住民税及び事業税 Current income taxes	7,901	6,203	4,679	△ 3,222	△ 40.8%	△ 1,027	△ 16.6%
法人税等調整額 Deferred income taxes	△ 277		496	774	—		
当期純利益(△:損失) Net income(△:loss)	19,908	14,536	16,047	△ 3,860	△ 19.4%	1,511	10.4%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	58	36	35	△ 22	△ 38.5%	△ 0	△ 1.0%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	19,849	14,500	16,012	△ 3,837	△ 19.3%	1,512	10.4%
設備投資額(有形・無形) Capital expenditures	13,180	10,029	6,516	△ 6,664	△ 50.6%	△ 3,512	△ 35.0%
減価償却費(有形・無形) Depreciation and Amortization	3,554	4,068	4,050	495	13.9%	△ 17	△ 0.4%
のれん償却額 Amortization of goodwill	500	599	599	98	19.8%	—	—

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2018年 3月期 FY2018	2019年 3月期 FY2019	2020年 3月期 FY2020	2021年 3月期 FY2021	2022年 3月期 FY2022	2023年 3月期 FY2023	前期対比 Change from FY2022	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	268,142	277,443	281,191	278,443	300,918	350,665	49,746	16.5%
売上原価 <i>Cost of sales</i>	163,529	168,694	172,574	162,849	187,376	230,723	43,346	23.1%
(売上高原価率) <i>(Ratio to Net sales)</i>	61.0%	60.8%	61.4%	58.5%	62.3%	65.8%	+3.5pt	5.7%
売上総利益 <i>Gross profit</i>	104,612	108,749	108,617	115,594	113,541	119,941	6,399	5.6%
販売費及び一般管理費 <i>SG&A expenses</i>	88,999	90,945	92,781	93,999	70,187	81,996	11,808	16.8%
(売上高販管費率) <i>(Ratio to Net sales)</i>	33.2%	32.8%	33.0%	33.8%	23.3%	23.4%	+0.1pt	0.3%
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	15,612	17,804	15,836	21,595	43,354	37,945	Δ 5,408	Δ 12.5%
(売上高営業利益率) <i>(Ratio to Net Sales)</i>	5.8%	6.4%	5.6%	7.8%	14.4%	10.8%	-3.6pt	Δ 24.9%
販売促進費、販売促進引当金繰入 <i>Sales promotion and allowance for s.p.</i>	33,688	34,012	35,073	34,128	3,883	4,220	337	8.7%
(売上高販促費率) <i>(Ratio to Net sales)</i>	12.6%	12.3%	12.5%	12.3%	1.3%	1.2%	-0.1pt	Δ 6.7%
研究開発費 <i>R&D expenses</i>	5,063	4,708	4,259	5,914	6,484	8,949	2,464	38.0%
(売上高研究開発費率) <i>(Ratio to Net sales)</i>	1.9%	1.7%	1.5%	2.1%	2.2%	2.6%	+0.4pt	18.4%
設備投資額(有形・無形) <i>Capital expenditures</i>	6,414	10,671	14,195	13,775	16,213	14,165	Δ 2,047	Δ 12.6%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	6,430	6,490	7,626	8,068	8,425	9,118	693	8.2%
のれん償却額 <i>Amortization of goodwill</i>	843	865	847	865	875	998	123	14.1%

宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2018年 3月期 FY2018	2019年 3月期 FY2019	2020年 3月期 FY2020	2021年 3月期 FY2021	2022年 3月期 FY2022	2023年 3月期 FY2023	前期対比 Change from FY2022	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	149,839	152,457	153,141	152,537	119,710	122,921	3,211	2.7%
売上原価 <i>Cost of sales</i>	89,681	91,441	92,822	92,439	90,898	93,645	2,747	3.0%
(売上高原価率) <i>(Ratio to Net sales)</i>	59.9%	60.0%	60.6%	60.6%	75.9%	76.2%	+0.3pt	0.3%
売上総利益 <i>Gross profit</i>	60,158	61,015	60,318	60,098	28,811	29,276	464	1.6%
販売費及び一般管理費 <i>SG&A expenses</i>	54,589	55,067	56,142	55,218	24,676	24,385	Δ 290	Δ 1.2%
(売上高販管費率) <i>(Ratio to Net sales)</i>	36.4%	36.1%	36.7%	36.2%	20.6%	19.8%	-0.8pt	Δ 3.8%
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	5,569	5,948	4,175	4,879	4,135	4,890	754	18.3%
(売上高営業利益率) <i>(Ratio to Net sales)</i>	3.7%	3.9%	2.7%	3.2%	3.5%	4.0%	+0.5pt	15.2%
販売促進費、販売促進引当金繰入 <i>Sales promotion and allowance for s.p.</i>	32,342	32,658	33,844	32,981	2,423	2,457	34	1.4%
(売上高販促費率) <i>(Ratio to Net sales)</i>	21.6%	21.4%	22.1%	21.6%	2.0%	2.0%	-0.0pt	Δ 1.2%
設備投資額(有形・無形) <i>Capital expenditures</i>	2,696	3,128	5,520	1,430	1,785	2,763	978	54.8%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	2,225	2,248	2,736	2,848	2,590	2,467	Δ 122	Δ 4.7%

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2018年 3月期 FY2018	2019年 3月期 FY2019	2020年 3月期 FY2020	2021年 3月期 FY2021	2022年 3月期 FY2022	2023年 3月期 FY2023	前期対比 Change from FY2022	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	70,717	77,834	82,765	69,589	102,186	137,483	35,297	34.5%
売上原価 <i>Cost of sales</i>	49,843	54,823	58,882	48,983	70,045	95,088	25,043	35.8%
(売上高原価率) <i>(Ratio to Net sales)</i>	70.5%	70.4%	71.1%	70.4%	68.5%	69.2%	+0.6pt	0.9%
売上総利益 <i>Gross profit</i>	20,874	23,010	23,883	20,605	32,140	42,394	10,254	31.9%
販売費及び一般管理費 <i>SG&A expenses</i>	16,480	18,478	20,351	19,562	23,667	31,573	7,905	33.4%
(売上高販管費率) <i>(Ratio to Net sales)</i>	23.3%	23.7%	24.6%	28.1%	23.2%	23.0%	-0.2pt	Δ 0.8%
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	4,393	4,532	3,532	1,043	8,472	10,821	2,348	27.7%
(売上高営業利益率) <i>(Ratio to Net sales)</i>	6.2%	5.8%	4.3%	1.5%	8.3%	7.9%	-0.4pt	Δ 5.1%
設備投資額(有形・無形) <i>Capital expenditures</i>	1,677	1,162	2,696	2,802	844	4,704	3,860	457.4%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	938	1,013	1,434	1,430	1,675	2,043	367	22.0%
のれん償却額 <i>Amortization of goodwill</i>	353	362	350	379	374	399	24	6.5%

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2018年 3月期 FY2018	2019年 3月期 FY2019	2020年 3月期 FY2020	2021年 3月期 FY2021	2022年 3月期 FY2022	2023年 3月期 FY2023	前期対比 Change from FY2022	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	32,312	35,841	34,565	46,086	67,699	78,142	10,442	115.4%
売上原価 <i>Cost of sales</i>	13,657	15,155	13,459	14,214	18,488	33,377	14,888	180.5%
(売上高原価率) <i>(Ratio to Net sales)</i>	42.3%	42.3%	38.9%	30.8%	27.3%	42.7%	+15.4pt	—
売上総利益 <i>Gross profit</i>	18,655	20,685	21,105	31,872	49,211	44,765	Δ 4,445	91.0%
販売費及び一般管理費 <i>SG&A expenses</i>	15,099	15,221	14,830	17,919	20,309	24,224	3,914	119.3%
(売上高販管費率) <i>(Ratio to Net sales)</i>	46.7%	42.5%	42.9%	38.9%	30.0%	31.0%	+1.0pt	—
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	3,555	5,463	6,274	13,952	28,902	20,541	Δ 8,360	71.1%
(売上高営業利益率) <i>(Ratio to Net sales)</i>	11.0%	15.2%	18.2%	30.3%	42.7%	26.3%	-16.4pt	—
研究開発費 <i>R&D expenses</i>	4,653	4,337	3,869	5,545	6,109	8,575	2,466	140.4%
(売上高研究開発費率) <i>(Ratio to Net sales)</i>	14.4%	12.1%	11.2%	12.0%	9.0%	11.0%	+1.9pt	—
設備投資額(有形・無形) <i>Capital expenditures</i>	1,539	6,002	5,365	8,897	13,180	6,516	Δ 6,664	49.4%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	2,568	2,691	2,921	3,220	3,554	4,050	495	113.9%
のれん償却額 <i>Amortization of goodwill</i>	489	502	496	486	500	599	98	119.8%

6. 2023年3月期 参考資料 :Reference Data for the Year Ended March 31, 2023

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries
(円 : Yen)

	2022年3月期 FY2022	2023年3月期 FY2023_Jan. 1, 2022 - Dec.31, 2022	
	実績 Actual (a)	実績 Actual (b)	前期差 Change(b-a)
米ドル : US dollar	109.90	131.64	21.74
ポンド: Pound	151.17	162.02	10.85
ユーロ: Euro	129.91	138.15	8.24
人民元: Yuan	17.04	19.50	2.46
100ウォン: 100 Won	9.60	10.18	0.58
インドルピー: Rupee	1.49	1.67	0.18
スウェーデンクローナ :Sweden krona	12.81	12.99	0.18
シンガポールドル :Singapore dollar	81.77	95.40	13.63
オーストラリアドル :Australian dollar	82.50	91.13	8.63

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)	
	対前期 Change from FY2022
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	20,575
宝酒造インターナショナルグループ 計 Net sales of Takara Shuzo International Group	16,336
海外酒類事業 Overseas Alcoholic beverages business	2,401
海外日本食材卸事業 Japanese food wholesale business in overseas markets	14,330
その他および調整額 Other / Adjustment	△ 396
タカラバイオグループ 計 Net sales of Takara Bio Group	4,238
試薬 Reagents	3,755
機器 Instruments	63
受託 CDMO	75
遺伝子医療 Gene Therapy	343

② 海外売上高比率の推移 :Change in overseas sales ratio

	2022年3月期 実績 FY2022 Actual			2023年3月期 実績 FY2023 Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	119,710	—	—	122,921	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	102,186	101,767	99.6%	137,483	136,900	99.6%
タカラバイオグループ Takara Bio Group	67,699	33,623	49.7%	78,142	32,475	41.6%
その他および調整額 Other / Adjustment	11,322	—	—	12,117	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	300,918	135,390	45.0%	350,665	169,375	48.3%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2022年3月期 実績 FY2022 Actual		2023年3月期 実績 FY2023 Actual	
		売上高 Net Sales	営業利益 Operating income(Δ,loss)	売上高 Net Sales	営業利益 Operating income(Δ,loss)
米国宝酒造 Takara Sake USA Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	40,704 4,473	5,887 647	46,041 6,060	5,007 659
宝酒造食品 (中国) Takara Shuzo Foods Co.,Ltd. (China)	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	62,563 1,066	4,407 75	40,858 796	Δ 4,194 Δ 81
トマーチン (英国) The Tomatin Distillery Co.,Ltd (U.K.)	千 ポンド :Thousands of Pound 百 万 円 :Millions of Yen	25,392 3,838	9,076 1,372	31,190 5,053	11,191 1,813
エイジ・インターナショナル (米国) AGE INTERNATIONAL,INC. (U.S.)	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	36,953 4,061	16,934 1,861	43,445 5,719	20,330 2,676
フーデックスグループ (欧州) FOODEX Group (Europe)	千 ユーロ :Thousands of Euro 百 万 円 :Millions of Yen	226,841 29,469	23,558 3,060	265,016 36,611	19,110 2,640
タザキフーズ (英国) TAZAKI FOODS LTD. (U.K.)	千 ポンド :Thousands of Pound 百 万 円 :Millions of Yen	53,010 8,013	2,227 336	69,068 11,190	1,602 259
ミューチャルトレーディング (米国) Mutual Trading Co., Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	418,794 46,025	16,258 1,786	499,304 65,728	27,344 3,599
ニッポンフード (豪州) Nippon Food Supplies Company Pty Ltd (Austraria)	千 AUS ドル :Thousands of Australian dollar 百 万 円 :Millions of Yen	54,177 4,469	4,040 333	62,910 5,733	4,601 419
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	11,679	645	13,634	791
タカラバイオヨーロッパS.A.S. (連結) Takara Bio Europe S.A.S. Consolidated	千 ユーロ :Thousands of Euro 百 万 円 :Millions of Yen	63,735 8,279	11,850 1,539	35,142 4,854	1,329 183
宝生物工程(大連) Takara Biotechnology (Dalian) Co.,Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	289,944 4,940	81,664 1,391	277,254 5,406	72,579 1,415
宝日医生物技術(北京) Takara Biomedical Technology(Beijing) Co., Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	692,533 11,800	111,892 1,906	553,735 10,797	84,306 1,643
タカラリアバイオメディカル Takara Korea Biomedical Inc.	百 万 ウォン :Millions of Won 百 万 円 :Millions of Yen	12,807 1,229	2,059 197	14,260 1,451	2,307 234
タカラバイオDSSインド DSS Takara Bio India Private Limited	千 インド・ルピー :Thousands of Rupee 百 万 円 :Millions of Yen	676,136 1,007	99,845 148	612,174 1,022	47,856 79
タカラバイオUSA Takara Bio USA, Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	124,580 13,691	17,591 1,933	132,657 17,462	22,571 2,971

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo
(百万円 :Millions of Yen)

	対前期増減 Change from FY2022		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	+464	+772	Δ 308
(参考) 原価コストダウン Reference :Cost reduction	Δ 5,244 ※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「Δ」で表示
*An increasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結) 要約損益計算書(p.1)における「その他」の内訳
Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)
(百万円 :Millions of Yen)

		2022年3月期 実績 FY2022 Actual		2023年3月期 実績 FY2023 Actual	
		売上高 Net Sales	営業利益 Operating income(Δ,loss)	売上高 Net Sales	営業利益 Operating income(Δ,loss)
物流事業 Transportation		13,904	613	13,548	579
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)		502	416	503	415
その他 Other		16,312	1,192	16,899	1,298
「その他」計 Total "Other"		30,719	2,222	30,950	2,293

7. 2024年3月期 業績予想 :Financial forecast for the year ending March 31, 2024

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2023年3月期 通期	2024年3月期 通期	対前期 Change from FY2023		2023年3月期 第2四半期累計	2024年3月期 第2四半期累計	対前期 Change from FY2023(1Q-2Q)	
	実績 FY2023 Actual (a)	予想 FY2024 Forecast (b)	増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)	実績 FY2023(1Q-2Q) Actual (c)	予想 FY2024(1Q-2Q) Forecast (d)	増減 Change (d-c)	率(d/c-1) YOY% (d/c-1)
宝酒造 Takara Shuzo	122,921	123,526	604	0.5%	61,820	61,621	△ 199	△ 0.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	137,483	165,700	28,216	20.5%	63,730	80,017	16,286	25.6%
タカラバイオ グループ Takara Bio Group	78,142	53,300	△ 24,842	△ 31.8%	32,587	22,800	△ 9,787	△ 30.0%
その他 Other	30,950	31,215	264	0.9%	15,577	15,308	△ 269	△ 1.7%
調整額 Adjustment	△ 18,832	△ 18,741	91	—	△ 9,435	△ 9,746	△ 310	—
売上高 Net sales	350,665	355,000	4,334	1.2%	164,279	170,000	5,720	3.5%
売上原価 Cost of sales	230,723	234,100	3,376	1.5%	106,400	113,652	7,251	6.8%
売上総利益 Gross profit	119,941	120,900	958	0.8%	57,879	57,126	△ 753	△ 1.3%
運送費、保管料 Transportation and storage	13,119	14,200	1,080	8.2%	6,468	6,920	451	7.0%
広告宣伝費 Advertising	2,840	3,400	559	19.7%	1,176	1,474	297	25.3%
販売促進費 Sales promotion	4,220	6,300	2,079	49.3%	1,850	2,723	872	47.1%
研究開発費 Research and development	8,949	9,400	450	5.0%	4,034	4,689	654	16.2%
管理費、その他 Other, net	52,866	61,300	8,433	16.0%	24,734	30,128	5,393	21.8%
販売費及び一般管理費 SG&A expenses	81,996	94,600	12,603	15.4%	38,264	45,936	7,671	20.0%
宝酒造 Takara Shuzo	4,890	4,541	△ 349	△ 7.1%	2,059	2,659	599	29.1%
宝酒造インターナショナルグループ Takara Shuzo International Group	10,821	12,500	1,678	15.5%	5,658	5,728	69	1.2%
タカラバイオ グループ Takara Bio Group	20,541	8,000	△ 12,541	△ 61.1%	10,870	2,100	△ 8,770	△ 80.7%
その他 Other	2,293	2,327	33	1.4%	1,243	1,135	△ 108	△ 8.7%
調整額 Adjustment	△ 601	△ 1,068	△ 466	—	△ 216	△ 521	△ 304	—
営業利益(△:損失) Operating income(△:loss)	37,945	26,300	△ 11,645	△ 30.7%	19,614	11,100	△ 8,514	△ 43.4%
受取利息・配当金 Interest and Dividends income	1,066	1,000	△ 66	△ 6.2%	531	532	0	0.1%
その他営業外収益 Other, net	612	400	△ 212	△ 34.7%	366	114	△ 252	△ 68.9%
営業外収益 Non-operating income	1,678	1,400	△ 278	△ 16.6%	898	646	△ 252	△ 28.1%
支払利息 Interest and discounts expenses	324	450	125	38.5%	149	196	46	31.1%
その他営業外費用 Other, net	593	450	△ 143	△ 24.1%	390	147	△ 243	△ 62.3%
営業外費用 Non-operating expenses	917	900	△ 17	△ 1.9%	539	343	△ 196	△ 36.5%
経常利益(△:損失) Ordinary income(△:loss)	38,706	26,800	△ 11,906	△ 30.8%	19,972	11,400	△ 8,572	△ 42.9%
特別利益 Extraordinary gain	1,681	8	△ 1,673	△ 99.5%	967	8	△ 959	△ 99.2%
特別損失 Extraordinary loss	694	508	△ 186	△ 26.9%	125	115	△ 10	△ 8.2%
税金等調整前当期純利益(△:損失) Income(△:loss) before income taxes	39,692	26,300	△ 13,392	△ 33.7%	20,815	11,386	△ 9,429	△ 45.3%
法人税、住民税及び事業税 Current income taxes	10,144	8,200	△ 2,801	△ 25.5%	5,405	3,695	△ 2,290	△ 38.3%
法人税等調整額 Deferred income taxes	857				580			
当期純利益(△:損失) Net income(△:loss)	28,690	18,100	△ 10,590	△ 36.9%	14,829	7,690	△ 7,139	△ 48.1%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	7,483	3,100	△ 4,383	△ 58.6%	3,956	958	△ 2,998	△ 75.8%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent	21,206	15,000	△ 6,206	△ 29.3%	10,873	6,700	△ 4,173	△ 38.4%
設備投資額(有形・無形) Capital expenditures	14,165	24,307	10,142	71.6%	3,513			
減価償却費(有形・無形) Depreciation and Amortization	9,118	10,200	1,081	11.9%	4,336	4,750	413	9.5%
のれん償却額 Amortization of goodwill	998	1,100	101	10.2%	472	550	77	16.4%

② 宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2023年3月期 通期	2024年3月期 通期	対前期 Change from FY2023		2023年3月期 第2四半期累計	2024年3月期 第2四半期累計	対前期 Change from FY2023(1Q-2Q)	
	実績 FY2023 Actual (a)	予想 FY2024 Forecast (b)	増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)	実績 FY2023(1Q-2Q) Actual (c)	予想 FY2024(1Q-2Q) Forecast (d)	増減 Change (d-c)	率(d/c-1) YOY% (d/c-1)
焼酎 Shochu	36,597	33,401	△ 3,196	△ 8.7%	19,998	17,374	△ 2,624	△ 13.1%
清酒 Sake	12,145	11,518	△ 627	△ 5.2%	4,697	4,456	△ 241	△ 5.1%
ソフトアルコール飲料 Light-alcohol refreshers	40,069	42,391	2,321	5.8%	20,525	21,811	1,285	6.3%
その他酒類 Other liquors	5,328	5,039	△ 289	△ 5.4%	2,823	2,702	△ 121	△ 4.3%
本みりん Hon Mirin	9,477	9,697	219	2.3%	4,710	4,701	△ 9	△ 0.2%
その他調味料 Other seasonings	8,780	8,860	79	0.9%	4,321	4,343	21	0.5%
原料用アルコール等 Raw alcohol	10,522	12,618	2,095	19.9%	4,743	6,231	1,487	31.3%
売上高 Net sales	122,921	123,526	604	0.5%	61,820	61,621	△ 199	△ 0.3%
売上原価 Cost of sales	93,645	92,389	△ 1,256	△ 1.3%	47,765	46,304	△ 1,461	△ 3.1%
売上総利益 Gross profit	29,276	31,137	1,860	6.4%	14,055	15,317	1,261	9.0%
運送費、保管料 Transportation and storage	7,857	8,036	178	2.3%	4,029	3,875	△ 154	△ 3.8%
広告宣伝費 Advertising	2,626	2,975	348	13.3%	1,099	1,270	170	15.5%
販売促進費 Sales promotion	2,457	3,988	1,530	62.3%	1,072	1,647	574	53.6%
研究開発費 Research and development	367	429	61	16.8%	177	211	33	19.1%
管理費、その他 Other, net	11,076	11,168	91	0.8%	5,617	5,652	34	0.6%
販売費及び一般管理費 SG&A expenses	24,385	26,596	2,210	9.1%	11,996	12,658	661	5.5%
営業利益(△:損失) Operating income(Δ:loss)	4,890	4,541	△ 349	△ 7.1%	2,059	2,659	599	29.1%
営業外収益 Non-operating income	544	317	△ 227	△ 41.8%	397	248	△ 149	△ 37.6%
営業外費用 Non-operating expenses	567	230	△ 337	△ 59.5%	362	108	△ 254	△ 70.2%
経常利益(△:損失) Ordinary income(Δ:loss)	4,867	4,628	△ 239	△ 4.9%	2,094	2,799	704	33.7%
特別利益 Extraordinary gain	63	8	△ 55	△ 87.3%	63	8	△ 55	△ 87.3%
特別損失 Extraordinary loss	234	416	181	77.2%	94	108	13	14.8%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	4,696	4,220	△ 476	△ 10.1%	2,063	2,699	635	30.8%
法人税等 Current income taxes, etc.	1,277	1,305	△ 153	△ 10.5%	761	804	190	31.0%
法人税等調整額 Deferred income taxes	181				△ 147			
当期純利益(△:損失) Net income(Δ:loss)	3,237	2,915	△ 322	△ 10.0%	1,449	1,895	445	30.7%
設備投資額(有形・無形) Capital expenditures	2,763	4,774	2,010	72.7%	638			
減価償却費(有形・無形) Depreciation and Amortization	2,467	2,684	216	8.8%	1,190	1,257	66	5.5%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

	(百万円 :Millions of Yen)							
	2023年3月期 通期	2024年3月期 通期	対前期 Change from FY2023		2023年3月期 第2四半期累計	2024年3月期 第2四半期累計	対前期 Change from FY2023(1Q-2Q)	
	実績 FY2023 Actual (a)	予想 FY2024 Forecast (b)	増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)	実績 FY2023(1Q-2Q) Actual (c)	予想 FY2024(1Q-2Q) Forecast (d)	増減 Change (d-c)	率(d/c-1) YOY% (d/c-1)
海外酒類事業 Overseas Alcoholic beverages business	18,253	21,106	2,852	15.6%	8,287	10,096	1,808	21.8%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	121,354	147,207	25,852	21.3%	56,421	71,216	14,794	26.2%
その他 Other	2,847	247	△ 2,600	△ 91.3%	2,812	206	△ 2,606	△ 92.7%
連結消去 Elimination	△ 4,972	△ 2,861	2,111	—	△ 3,791	△ 1,502	2,289	—
売上高 Net sales	137,483	165,700	28,216	20.5%	63,730	80,017	16,286	25.6%
売上原価 Cost of sales	95,088	113,505	18,416	19.4%	43,748	55,127	11,378	26.0%
売上総利益 Gross profit	42,394	52,195	9,800	23.1%	19,981	24,890	4,908	24.6%
運送費、保管料 Transportation and storage	4,883	5,859	975	20.0%	2,253	2,848	594	26.4%
広告宣伝費 Advertising	136	193	56	41.6%	50	86	35	68.8%
販売促進費 Sales promotion	1,109	1,368	258	23.2%	486	603	116	24.0%
管理費、その他 Other, net	25,443	32,275	6,831	26.9%	11,532	15,623	4,090	35.5%
販売費及び一般管理費 SG&A expenses	31,573	39,695	8,121	25.7%	14,322	19,161	4,838	33.8%
海外酒類事業 Overseas Alcoholic beverages business	4,895	5,860	964	19.7%	2,466	2,612	145	5.9%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	7,559	8,837	1,277	16.9%	4,002	4,197	194	4.9%
その他 Other	1,700	△ 1,320	△ 3,020	—	2,232	△ 515	△ 2,747	—
連結消去 Elimination	△ 3,334	△ 877	2,457	—	△ 3,042	△ 565	2,477	—
営業利益(△:損失) Operating income(△:loss)	10,821	12,500	1,678	15.5%	5,658	5,728	69	1.2%
営業外収益 Non-operating income	315	166	△ 149	△ 47.4%	187	64	△ 123	△ 65.9%
営業外費用 Non-operating expenses	169	337	167	98.7%	76	141	64	84.6%
経常利益(△:損失) Ordinary income(△:loss)	10,967	12,329	1,361	12.4%	5,769	5,651	△ 118	△ 2.1%
特別利益 Extraordinary gain	8	—	△ 8	—	0	—	△ 0	—
特別損失 Extraordinary loss	68	38	△ 30	△ 44.5%	1	—	△ 1	—
税金等調整前当期純利益(△:損失) Income(△:loss) before income taxes	10,907	12,291	1,383	12.7%	5,769	5,650	△ 119	△ 2.1%
法人税等 Current income taxes, etc.	3,255	3,540	255	7.8%	1,709	1,676	47	2.9%
法人税等調整額 Deferred income taxes	28				△ 81			
当期純利益(△:損失) Net income(△:loss)	7,623	8,751	1,127	14.8%	4,141	3,973	△ 168	△ 4.1%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	1,189	984	△ 205	△ 17.2%	585	474	△ 111	△ 19.0%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent	6,434	7,767	1,332	20.7%	3,555	3,498	△ 57	△ 1.6%
設備投資額(有形・無形) Capital expenditures	4,704	3,187	△ 1,517	△ 32.3%	750			
減価償却費(有形・無形) Depreciation and Amortization	2,043	2,416	372	18.3%	904	1,187	283	31.3%
のれん償却額 Amortization of goodwill	399	534	134	33.7%	192	267	74	39.0%

④ タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2023年3月期 通期 実績 FY2023 Actual (a)	2024年3月期 通期 予想 FY2024 Forecast (b)	対前期 Change from FY2023		2023年3月期 第2四半期累計 実績 FY2023(1Q-2Q) Actual (c)	2024年3月期 第2四半期累計 予想 FY2024(1Q-2Q) Forecast (d)	対前期 Change from FY2023(1Q-2Q)	
			増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)			増減 Change (d-c)	率(d/c-1) YOY% (d/c-1)
試薬 Reagents	65,925	38,353	△ 27,572	△ 41.8%	27,565	18,081	△ 9,484	△ 34.4%
機器 Instruments	1,375	2,019	643	46.8%	694	904	209	30.2%
受託 CDMO	8,200	9,914	1,713	20.9%	3,183	2,761	△ 422	△ 13.3%
遺伝子医療 Gene Therapy	2,640	3,012	371	14.1%	1,144	1,052	△ 92	△ 8.0%
売上高 Net sales	78,142	53,300	△ 24,842	△ 31.8%	32,587	22,800	△ 9,787	△ 30.0%
売上原価 Cost of sales	33,377	19,315	△ 14,062	△ 42.1%	10,562	7,684	△ 2,878	△ 27.2%
売上総利益 Gross profit	44,765	33,984	△ 10,781	△ 24.1%	22,025	15,115	△ 6,910	△ 31.4%
運送費、保管料 Transportation and storage	653	691	37	5.8%	330	337	6	2.0%
広告宣伝費 Advertising	48	74	25	52.4%	21	36	14	64.5%
販売促進費 Sales promotion	699	965	265	37.9%	306	480	173	56.4%
研究開発費 Research and development	8,575	9,000	424	4.9%	3,853	4,471	617	16.0%
管理費、その他 Other, net	14,247	15,253	1,005	7.1%	6,641	7,689	1,047	15.8%
販売費及び一般管理費 SG&A expenses	24,224	25,984	1,759	7.3%	11,154	13,015	1,860	16.7%
営業利益(△:損失) Operating income(△:loss)	20,541	8,000	△ 12,541	△ 61.1%	10,870	2,100	△ 8,770	△ 80.7%
営業外収益 Non-operating income	363	386	22	6.3%	170	90	△ 80	△ 47.3%
営業外費用 Non-operating expenses	221	186	△ 35	△ 16.2%	85	90	4	5.6%
経常利益(△:損失) Ordinary income(△:loss)	20,682	8,200	△ 12,482	△ 60.4%	10,955	2,100	△ 8,855	△ 80.8%
特別利益 Extraordinary gain	930	—	△ 930	—	902	—	△ 902	—
特別損失 Extraordinary loss	388	59	△ 329	△ 84.8%	27	5	△ 22	△ 81.6%
税金等調整前当期純利益(△:損失) Income(△:loss) before income taxes	21,224	8,140	△ 13,084	△ 61.6%	11,831	2,094	△ 9,737	△ 82.3%
法人税等 Current income taxes, etc.	4,679	2,612	△ 2,564	△ 49.5%	2,538	880	△ 2,379	△ 73.0%
法人税等調整額 Deferred income taxes	496				721			
当期純利益(△:損失) Net income(△:loss)	16,047	5,528	△ 10,519	△ 65.6%	8,572	1,214	△ 7,358	△ 85.8%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	35	28	△ 7	△ 21.8%	33	14	△ 19	△ 58.4%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent	16,012	5,500	△ 10,512	△ 65.7%	8,538	1,200	△ 7,338	△ 85.9%
設備投資額(有形・無形) Capital expenditures	6,516	16,024	9,508	145.9%	2,056			
減価償却費(有形・無形) Depreciation and Amortization	4,050	4,590	539	13.3%	1,962	2,182	219	11.2%
のれん償却額 Amortization of goodwill	599	637	37	6.3%	280	318	37	13.4%

8. 2024年3月期 参考資料 :Reference Data for the year ending March 31, 2024

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2023年3月期	2024年3月期	
	FY2023	FY2024 Jan. 1, 2023 - Dec.31, 2023	
	実績 Actual (a)	予想 Forecast announced Feb. 2023 (b)	前期差 Change(b-a)
米ドル : US dollar	131.64	140.00	8.36
ポンド: Pound	162.02	162.00	△ 0.02
ユーロ: Euro	138.15	141.00	2.85
人民元: Yuan	19.50	19.50	0.00
100ウォン: 100 Won	10.18	10.10	△ 0.08
インドルピー: Rupee	1.67	1.70	0.03
スウェーデンクローナ :Sweden krona	12.99	13.00	0.01
シンガポールドル :Singapore dollar	95.40	99.50	4.10
オーストラリアドル :Australian dollar	91.13	91.70	0.57

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2023
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	7,612
宝酒造インターナショナルグループ 計 Net sales of Takara Shuzo International Group	6,531
海外酒類事業 Overseas Alcoholic beverages business	788
海外日本食材卸事業 Japanese food wholesale business in overseas markets	5,903
その他および調整額 Other / Adjustment	△ 160
タカラバイオグループ 計 Net sales of Takara Bio Group	1,081
試薬 Reagents	912
機器 Instruments	42
受託 CDMO	1
遺伝子医療 Gene Therapy	123

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2023年3月期通期実績			2024年3月期通期予想		
	FY2023 Actual			FY2024 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	122,921	—	—	123,526	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	137,483	136,900	99.6%	165,700	165,153	99.7%
タカラバイオグループ Takara Bio Group	78,142	32,475	41.6%	53,300	34,543	64.8%
その他および調整額 Other / Adjustment	12,117	—	—	12,474	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	350,665	169,375	48.3%	355,000	199,697	56.3%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2023年3月期 FY2023 Actual		2024年3月期 予想 FY2024 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ,loss)	売上高 Net Sales	営業利益 Operating income(Δ,loss)
米国宝酒造 Takara Sake USA Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	46,041 6,060	5,007 659	49,509 6,931	5,900 826
宝酒造食品（中国） Takara Shuzo Foods Co.,Ltd. (China)	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	40,858 796	Δ 4,194 Δ 81	56,909 1,109	1,014 19
トマーチン（英国） The Tomatin Distillery Co.,Ltd (U.K.)	千 ポ ンド :Thousands of Pound 百 万 円 :Millions of Yen	31,190 5,053	11,191 1,813	36,664 5,939	13,648 2,210
エイジ・インターナショナル（米国） AGE INTERNATIONAL,INC. (U.S.)	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	43,445 5,719	20,330 2,676	45,063 6,308	18,601 2,604
フーデックス7社連結（欧州） FOODEX Group (Europe)	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	182,053 25,150	11,684 1,614	203,436 28,684	14,512 2,046
コムポート・ケタフーズ（欧州） Cominport Distribución S.L., Keta Foods, Lda (Europe)	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	89,265 12,332	7,428 1,026	103,039 14,528	8,557 1,206
タザキフーズ（英国） TAZAKI FOODS LTD. (U.K.)	千 ポ ンド :Thousands of Pound 百 万 円 :Millions of Yen	69,068 11,190	1,602 259	74,990 12,148	2,510 406
ミューチャルトレーディング（米国） Mutual Trading Co., Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	499,304 65,728	27,344 3,599	600,000 84,000	29,100 4,074
ニッポンフード（豪州） Nippon Food Supplies Company Pty Ltd (Austraria)	千 AUS ドル :Thousands of Australian dollar 百 万 円 :Millions of Yen	62,910 5,733	4,601 419	69,718 6,393	4,714 432
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	13,634	791	14,801	646
タカバイオヨーロッパS.A.S.（連結） Takara Bio Europe S.A.S. Consolidated	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	35,142 4,854	1,329 183	40,067 5,649	645 90
宝生物工程(大連) Takara Biotechnology (Dalian) Co.,Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	277,254 5,406	72,579 1,415	256,456 5,000	60,674 1,183
宝日医生物技術(北京) Takara Biomedical Technology(Beijing) Co., Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	553,735 10,797	84,306 1,643	539,351 10,517	64,637 1,260
タカラコアバイオメディカル Takara Korea Biomedical Inc.	百 万 ウ ォ ン :Millions of Won 百 万 円 :Millions of Yen	14,260 1,451	2,307 234	14,483 1,462	2,412 243
タカラバイオDSSインド DSS Takara Bio India Private Limited	千 イ ン ト ' ル ビ ' ー :Thousands of Rupee 百 万 円 :Millions of Yen	612,174 1,022	47,856 79	401,125 681	37,345 63
タカラバイオUSA Takara Bio USA, Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	132,657 17,462	22,571 2,971	140,289 19,640	18,821 2,634

(注)2023年3月期まで「フーデックスグループ」としていた「フーデックス7社連結」「コムポート・ケタフーズ」を、2024年3月期より分けて表記しております。
本表の2023年3月期実績は、当該変更を反映して組み替えております。

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo
(百万円 :Millions of Yen)

	対前期増減 Change from FY2023		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	+1860	+144	+1716
(参考)原価コストダウン Reference :Cost reduction	Δ 2,805 ※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「Δ」で表示
*An increasing factor and a decreasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結)業績予想(p.10)における「その他」の内訳
Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.10)
(百万円 :Millions of Yen)

	2023年3月期 FY2023 Actual		2024年3月期 予想 FY2024 Forecast	
	売上高 Net Sales	営業利益 Operating income(Δ,loss)	売上高 Net Sales	営業利益 Operating income(Δ,loss)
物流事業 Transportation	13,548	579	13,811	582
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	503	415	505	418
その他 Other	16,899	1,298	16,898	1,326
「その他」計 Total "Other"	30,950	2,293	31,215	2,327